Reme-D
Organization Details
Reme-D, established in December 2022, addresses critical testing shortages in Egypt and Africa, particularly highlighted by the COVID-19 pandemic. The company leverages nanotechnology and biotechnology to overcome limitations of imported testing kits from the US and EU, which are often expensive, require extensive cold chain logistics, and are unsuitable for low-resource settings.
Reme-D's patented technology produces tests with three key advantages:
- Room Temperature Stability: Eliminating the need for cold chain logistics and reducing associated costs.
- Simplified Usage: A testing protocol three times shorter than competitors, requiring less equipment.
- Affordability: Tests are six times more affordable than competing products.
These advantages directly address the challenges of limited access, high costs, and logistical complexities associated with imported testing kits, offering a more sustainable and accessible solution for diverse diagnostic needs across Africa.
Impact Story
Reme-D exists to address Africa's pressing diagnostic gaps by providing affordable, rapid testing solutions for infectious and non-infectious diseases that disproportionately affect the continent.
When considering infectious diseases, with 7.5 million people living with HIV in South Africa, 3.5 million in Nigeria, and 1.6 million in Kenya alone, the need for early detection is critical to curbing transmission and enabling life-saving antiretroviral therapy. Similarly, tuberculosis (TB) remains a dire challenge, with 2.5 million annual cases and 424,000 deaths in 2022, compounded by 700,000 missed diagnoses due to limited healthcare access.
The impact extends to hepatitis and dengue, where 91 million Africans live with Hepatitis B/C, and over 900 confirmed dengue cases have been reported in 2025 across Burkina Faso and Mali. Reme-D’s molecular diagnostics directly serve these populations by enabling early detection of HIV viral loads, TB co-infections, and hepatitis markers at lower costs. For example, faster TB diagnosis could help close the 30% detection gap, while affordable hepatitis testing addresses regions like West Africa, where prevalence reaches 10.09%. By partnering with governments and NGOs, Reme-D’s scalable solutions aim to reduce preventable deaths and accelerate progress toward the WHO’s 2025 TB reduction targets, ensuring equitable healthcare access for millions.
Finaly, we hopw that by showing how Africans can leverage science to solve African challenges, we can inspite other African scientists to innovate for Africa!
Diverse Social Enterprise
The TRANSFORM Support Hub is committed to accelerating diverse owned and led enterprises to build more equitable and resilient supply chains.
